Shannon Jaramillo
Family · Chino Valley, AZNPI 1124307186
Payments from drug & device makers
Across 294 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$705
- GSK$562
- Amgen$434
- Pfizer$431
- Novo Nordisk$417
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,60699%
- Entertainment$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 39 | $1,015 |
| AbbVie | 34 | $705 |
| GSK | 31 | $562 |
| Amgen | 33 | $434 |
| Pfizer | 27 | $431 |
| Novo Nordisk | 21 | $417 |
| Lilly USA, LLC | 21 | $261 |
| Exact Sciences | 9 | $165 |
| Edwards Lifesciences | 1 | $153 |
| Abbott | 7 | $148 |
| Bayer | 7 | $139 |
| Sanofi-aventis U.S. LLC | 9 | $139 |
| Boehringer Ingelheim | 6 | $121 |
| Astellas Pharma US Inc | 6 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Lucid Diagnostics Inc. | 4 | $81 |
| Biohaven Pharmaceuticals, Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $73 |
| Mylan Specialty L.p. | 3 | $66 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Indivior Inc. | 1 | $43 |
| Merck | 3 | $39 |
| Optos, Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| Renalytix AI, Inc. | 1 | $22 |
| Medtronic | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
| Novartis | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$384
- FARXIGA$384
- AIRSUPRA$265
- Edwards SAPIEN 3 Transcatheter Heart Valve$153
- UBRELVY$109
How this compares
$5,639 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 101 | $126,587 |
| OzempicSemaglutide | 99 | $98,458 |
| FarxigaDapagliflozin Propanediol | 50 | $56,838 |
| Nurtec OdtRimegepant Sulfate | 28 | $42,156 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $38,183 |
| QuliptaAtogepant | 34 | $37,760 |
| EliquisApixaban | 30 | $37,541 |
| Repatha SureclickEvolocumab | 44 | $26,209 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $20,909 |
| CreonLipase/Protease/Amylase | 21 | $18,783 |
| TrulicityDulaglutide | 13 | $17,252 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,012 |
| BelsomraSuvorexant | 11 | $10,074 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 47 | $8,292 |
| GemtesaVibegron | 11 | $6,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $261 | $143,839114 claims |
| Novo NordiskOzempic | $417 | $98,45899 claims |
| PfizerNurtec Odt, Eliquis | $431 | $79,69758 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,015 | $73,85076 claims |
| AbbVieQulipta, Creon, Synthroid | $705 | $57,92679 claims |
| GSKTrelegy Ellipta | $562 | $38,18334 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $139 | $20,90924 claims |
| MerckBelsomra | $39 | $10,07411 claims |
| Astellas Pharma US IncMyrbetriq | $114 | $5,69113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.
Other family in Chino Valley
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.